Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases
Authors:
- Luigi PortellaLPLuigi Portella
- Rosamaria VitaleRVRosamaria Vitale
- Stefania De LucaStefania De Luca
- Crescenzo D’alterioCDCrescenzo D’alterio
- Caterina IeranòCICaterina Ieranò
- Maria NapolitanoMNMaria Napolitano
- Anna RiccioARAnna Riccio
- Antonio BarbieriABAntonio Barbieri
- Antonio LucianoALAntonio Luciano
- Andrea CiarmielloACAndrea Ciarmiello
Open Access
- 13 September 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (9) , e74548
Abstract
The CXCR4/CXCL12 axis plays a role in cancer metastases, stem cell mobilization and chemosensitization. Proof of concept for efficient CXCR4 inhibition has been demonstrated in stem cell mobilization prior to autologous transplantation in hematological malignancies. Nevertheless CXCR4 inhibitors suitable for prolonged use as required for anticancer therapy are not available. To develop new CXCR4 antagonists a rational, ligand-based approach was taken, distinct from the more commonly used development strategy. A three amino acid motif (Ar-Ar-X) in CXCL12, also found in the reverse orientation (X-Ar-Ar) in the vMIP-II inhibitory chemokine formed the core of nineteen cyclic peptides evaluated for inhibition of CXCR4-dependent migration, binding, P-ERK1/2-induction and calcium efflux. Peptides R, S and I were chosen for evaluation in in vivo models of lung metastases (B16-CXCR4 and KTM2 murine osteosarcoma cells) and growth of a renal cells xenograft. Peptides R, S, and T significantly reduced the association of the 12G5-CXCR4 antibody to the receptor and inhibited CXCL12-induced calcium efflux. The four peptides efficiently inhibited CXCL12-dependent migration at concentrations as low as 10 nM and delayed CXCL12-mediated wound healing in PES43 human melanoma cells. Intraperitoneal treatment with peptides R, I or S drastically reduced the number of B16-CXCR4-derived lung metastases in C57/BL mice. KTM2 osteosarcoma lung metastases were also reduced in Balb/C mice following CXCR4 inhibition. All three peptides significantly inhibited subcutaneous growth of SN12C-EGFP renal cancer cells. A novel class of CXCR4 inhibitory peptides was discovered. Three peptides, R, I and S inhibited lung metastases and primary tumor growth and will be evaluated as anticancer agents.Keywords
This publication has 48 references indexed in Scilit:
- Inhibition of stromal CXCR4 impairs development of lung metastasesCancer Immunology, Immunotherapy, 2012
- Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4Leukemia, 2011
- CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?Clinical Cancer Research, 2011
- C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cellsProceedings of the National Academy of Sciences, 2010
- The Peptidomimetic CXCR4 Antagonist TC14012 Recruits β-Arrestin to CXCR7Journal of Biological Chemistry, 2010
- Recruitment of Myeloid but not Endothelial Precursor Cells Facilitates Tumor Regrowth after Local IrradiationCancer Research, 2010
- Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1α, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal CancerCancer Research, 2009
- Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7Proceedings of the National Academy of Sciences, 2007
- The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tractNature, 1998
- Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1Nature, 1996